Saul Kivimae

Company: Nektar Therapeutics

Job title: Vice President & Head of Pharmacology

Seminars:

Assessing Novel Therapeutically Active Anti-TNFR2 Agonistic Antibodies in Promoting Treg Proliferation and the Induction of Treg Functional Markers 11:30 am

Illuminating the unique properties of TNFR2 agonism for Treg targeted therapies Optimizing TNFR2 targeting on Tregs with novel approaches Showcasing preclinical data from Nektar’s differentiated TNFR2 agonistRead more

day: Day 1 Treg Modulators track AM